FAQ on Lantern Pharma Inc.'s Breakthrough in NSCLC Treatment with LP-300

What is the significance of Lantern Pharma’s recent announcement?

The announcement highlights a durable complete response in a never-smoker with advanced NSCLC treated with LP-300 in combination with standard chemotherapy, demonstrating the drug’s potential to meet critical unmet needs in this underserved patient group.

How does LP-300 work in treating NSCLC?

LP-300, developed using Lantern’s RADR(R) AI platform, is used in combination with standard chemotherapy to treat NSCLC, showing significant tumor reduction and complete resolution of lesions in a patient who had failed previous therapies.

Who is the patient that achieved a complete response in the HARMONIC(TM) trial?

The patient is a 70-year-old never-smoker with advanced NSCLC who had previously failed three lines of therapy, including Keytruda(R), radiation, and Tagrisso(R), before achieving a durable complete response with LP-300.

What is the RADR(R) AI platform?

RADR(R) is Lantern Pharma’s proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to accelerate oncology drug discovery and development.

How long has the patient remained progression-free after treatment with LP-300?

The patient has remained progression-free for nearly two years after the initiation of treatment with LP-300, experiencing no clinically significant adverse reactions across 21 cycles.

Where can I find more information about Lantern Pharma’s HARMONIC(TM) trial?

More information can be found in the full press release available at https://ibn.fm/R0c2m.

What makes never-smoker NSCLC patients a unique group?

Never-smoker NSCLC patients represent a growing, underserved segment with limited approved treatments, especially those who have exhausted targeted kinase therapy options, making LP-300’s success particularly significant.

How does Lantern Pharma accelerate drug development?

Lantern Pharma uses its RADR(R) AI platform to advance drug programs from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program, significantly reducing the cost and timeline of oncology drug development.

Where can investors find the latest news and updates about Lantern Pharma?

Investors can find the latest news and updates relating to LTRN in the company’s newsroom at https://ibn.fm/LTRN.